The Silence of the Bioethicists
By Leigh Turner,
Impact Ethics
| 03. 24. 2014
Last week, Kirstin Borgerson, a philosopher at Dalhousie University, published a
thoughtful commentary on my colleague Carl Elliott’s
persistent call for an investigation of Dan Markingson’s death and psychiatric research misconduct at the University of Minnesota. Dan Markingson was a young man from St. Paul who
committed suicide by nearly decapitating himself while enrolled in a psychiatric drug study at the University of Minnesota Medical Center, Fairview.In analyzing the audience’s response to Carl’s public lecture, alongside the typical response of her undergraduate students, Borgerson notes that there was no animated discussion of ethical issues in the Markingson case because “very simply, there is nothing to debate.” Borgerson adds,
Among serious scholars, there is no defense of the practice of: radically violating informed consent …; enrolling suicidal patients in the sort of risky trial that Markingson was enrolled in; having researchers disrespect and disregard concerns raised by family members about the well-being of research subjects during a trial; or creating conditions under which researchers are motivated to enroll subjects so as not to lose out on tens of thousands of...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Patrick Foong, BioNews | 11.03.2025